| 前收盘价格 | 3.71 |
| 成交量 | 951,892 |
| 预期市盈率 (P/E Forward) | 40.65 |
| 价格/销量 (P/S) | 2.07 |
| 股市价格/股市净资产 (P/B) | 6.60 |
| 52周波幅 |
| 营业毛利率 | -14.86% |
| 营业利益率 (TTM) | -49.04% |
| 稀释每股收益 (EPS TTM) | -0.230 |
| 季度收入增长率 (YOY) | 61.00% |
| 总债务/股东权益 (D/E MRQ) | 124.68% |
| 流动比率 (MRQ) | 4.12 |
| 营业现金流 (OCF TTM) | -47.54 M |
| 杠杆自由现金流 (LFCF TTM) | -17.22 M |
| 资产报酬率 (ROA TTM) | -6.58% |
| 股东权益报酬率 (ROE TTM) | -36.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Ardelyx, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | 5.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.50 |
|
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.51% |
| 机构持股比例 | 72.46% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合